Consistent with this, selonsertib (GS-4997), an ASK1 inhibitor developed as an antifibrotic agent for nonalcoholic steatohepatitis,16 reduced cardiac fibrosis, and remodeling in mice treated with Ang II. This evidence concerns the gene MAP3K5 and metabolic dysfunction-associated steatohepatitis.